Kobayashi K, Masuda N, Mizuno T, Miura K, et al. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03). Breast Cancer Res Treat 2023 Jul 22. doi: 10.1007/s10549-023-07030.
PMID: 37480384